Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 7/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864694 | 1.00 | KLK5 (0.53) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL7442384 | 1.00 | KLK5 (0.53) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2856826 | 0.94 | ITGB3 (0.52) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2856829 | 0.94 | ITGB3 (0.52) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL919043 | 0.91 | ITGB3 (0.49) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2858945 | 0.91 | ITGB3 (0.49) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2853779 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BCTSSCTSKABCB1 | |
| SCHEMBL1932580 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BCTSSCTSKABCB1 | |
| SCHEMBL2847835 | 0.91 | ITGB3 (0.61) | ITGB3ITGA2BCTSSCTSKABCB1 | |
| SCHEMBL16469894 | 0.90 | ITGB3 (0.48) | KLK5ITGB3ITGA2BCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053723-B | Sulfonamide derivatives and pharmaceutical use thereof | EA制药株式会社 | 2021-09-03 | — | — | CN | disclosed |
| EP-3318260-B1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3318260-B1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3318260-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3318260-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2187887-B1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2187887-B1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2017141193-A1 | PROCESS FOR THE PREPARATION OF SACUBITRIL OR SALTS THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-08-24 | — | — | WO | disclosed |
| CN-106414413-A | Sulfonamide derivatives and pharmaceutical use thereof | EA制药株式会社 | 2017-02-15 | — | — | CN | disclosed |
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | THE GENERAL HOSPITAL CORPORATION | 2016-11-17 | — | — | US | disclosed |
| EP-0592367-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| WO-1994005677-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-03-17 | — | — | WO | disclosed |
| US-5294632-A | Diuretics and vasorelaxants | CIBA-GEIGY CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| US-5273990-A | 5-Phosphonomethyleneamino aryl-substitued alkylene-1H-tetazoles | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
| US-5250522-A | Neutral endopeptidase inhibitors; cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
| US-5217996-A | Endopeptidase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-5182263-A | Appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | disclosed |
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331783-A1 | BISAMIDE COMPOUNDS AS ALLOSTERIC EFFECTORS FOR REDUCING THE OXYGEN-BINDING AFFINITY OF HEMOGLOBIN | HBB, HBG2, HBG1 | KLK5 3689/4885ITGB3 1504/4885ITGA2B 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.